The inhibitory receptor FcgRIIb regulates B-cell functions. Genetic studies have associated Fcgr2b polymorphisms and lupus susceptibility in both humans and murine models, in which B cells express reduced FcgRIIb levels. Furthermore, FcgRIIb absence results in lupus on the appropriate genetic background, and lentiviral-mediated FcgRIIb overexpression prevents disease in the NZM2410 lupus mouse. The NZM2410/NZW allele Fcgr2b is, however, located in-between Sle1a and Sle1b, two potent susceptibility loci, making it difficult to evaluate Fcr2b NZW independent contribution. By using two congenic strains that each carries only Sle1a (B6.Sle1a (15-353) NZW does not produce an autoimmune phenotype, but is associated with an increased number of class-switched plasma cells. These results show that while a lower level of FcgRIIb does not by itself induce the development of autoreactive B cells, it has the potential to amplify the contribution of autoreactive B cells induced by other lupus-susceptibility loci by enhancing the production of class-switched plasma cells.
Introduction
Both forward and reverse genetic approaches in lupus patients and in murine models have shown a high level of complexity in the mechanisms by which genetic variation contributes to lupus susceptibility. 1 A number of linkage and association studies have associated the Fc g receptors (FcgRs) with lupus susceptibility in both humans and mice. Among the FcgRs, FcgRIIB plays a unique role in inducing inhibitory signals in B cells upon immune complex binding. 2 In humans, a À343 G/C promoter polymorphism and a Ile232Thr transmembrane polymorphism, both associated with loss of function, have been associated with lupus. 3 The strength of the association between each of these polymorphisms and disease varied among populations, most likely due to interactions with other susceptibility alleles segregating differently among these populations. Functionally, two recent studies have reported that lupus patients present a defective upregulation of FcgRIIB expression in selected late B-cell developmental stages, namely, memory B cells and plasma cells (PC). 4, 5 In the mouse, FcgRIIB is required for the maintenance of systemic tolerance on a C57BL/6 (B6) background, 6 and a B-cell receptor transgenic model has suggested that it constitutes a checkpoint at the post-germinal center (GC)/plasma cell stage. 7 Several lupus-prone strains show reduced FcgRIIB levels attributed to a promoter region polymorphism for NZB, BXSB and MRL. 8, 9 However, using B6.Sle1/NZW and NZW mice, we have recently shown that failed upregulation of FcgRIIB on GC B cells is not associated with the promoter region polymorphism, but rather with additional polymorphisms in the putative regulatory regions 3 and 4 in the third intron shared by both NZB and NZW alleles. 10 A direct demonstration of the involvement of FcgRIIB in lupus pathogenesis was dramatically demonstrated in both the NZM2410 and BXSB models, in which full disease abrogation was achieved by partial restoration of FcgRIIB expression on hematopoeitic cells. 11 The B6.Sle1 congenic interval corresponds to the 37 cM long telomeric end of chromosome 1 derived from the NZM2410/NZW genome. 12 The location within this interval of the Fcgr2b gene makes this the primary candidate gene for the altered expression of FcgRIIB we observed on B6.Sle1 GC B cells. 10 However, it is not clear whether the polymorphisms in the FcgRIIB NZW allele alone are responsible for the perturbed expression of FcgRIIB on GC B cells in B6.Sle1 mice or whether other susceptibility genes located within the Sle1 interval might act epistatically in producing this altered expression. In addition, Fcgr2b is located between Sle1a and Sle1b, and we have reported that a congenic strain B6.Sle1(111-148) that contains Fcgr2b but lacks both Sle1a and Sle1b does not produce autoantibodies. 13 The B6.Sle1(111-148) strain contains in addition to Fcgr2b NZW a number of genes of NZW origin, including two FcR homolog genes Fcrla and FcRlb. It however allows the evaluation of Fcgr2b NZW independently from Sle1a and Sle1b. In the present study, we report that Fcgr2b NZW fails to upregulate on GC B cells independently from Sle1a and Sle1b, and that it is associated with a greater number of class-switched PCs in the spleen and bone marrow (BM).
Results
Perturbed upregulation of FcgRIIB expression on GC B cells in B6.Sle1 mice As previously described, 10 we have established an operative definition of GC B-cell phenotype for flow cytometry using peptide nucleic acid (PNA), in combination with anti-B220 and anti-IgD. Based on B220 and PNA staining, we first separated B220
hi mature B cells consisting of both PNA þ and PNA neg (rectangular gate, Figure 1a , left panel) populations from total lymphocytes obtained from sheep red blood cells (SRBC)-immunized C57BL/6 (B6) mice on day 9 of the immune response. We then defined B220 hi PNA neg IgD þ and B220 hi PNA þ IgD neg cells as non-GC and GC B cells, respectively (rectangular gates, Figure 1a , right panel).
Using these definitions, we first measured the levels of FcgRIIB on splenic B-cell subpopulations, by performing four-color flow cytometry analysis from B6 and B6.Sle1 mice on day 9 of the anti-SRBC response. Fcgr2b-deficient (B6.RIIB À/À ) mice were used as negative controls. The mAb 2.4G2 that recognizes the extracellular domains of both FcgRII and III was used since no mAb specific for the NZM2410/NZW/Sle1 FcgRIIB allele (Ly17.1 allotype) is available. As shown in Figure 1b, We also investigated whether the altered expression of FcgRIIB we observed by flow cytometry on B6.Sle1 GC B cells was apparent on GC B cells and follicular dendritic cells (FDCs) were defined histologically. Parallel spleen 14 and B6.Sle1(111-148), previously described as not producing autoantibodies. 13 A third intron deletion (Figure 2b ) specific to the NZW allele 10 determined that the Sle1a(15-353) interval contained the Fcgr2b B6 allele, mapping the telomeric recombination breakpoint between D1MIT270 (included) and Fcgr2b (excluded). In contrast, the Sle1(111-148) interval contained the Fcgr2b NZW allele, placing the telomeric recombination breakpoint between the Fcgr2b third intron (included) and D1MIT146 (excluded). We have not determined yet the exact location of the recombination breakpoint, and whether it is telomeric to the Fcgr2b promoter (Figure 2a, inset) . The two strains also differed by their centromeric region centered on the D1MIT15 marker, where Sle1a was mapped. 13 The NZW origin of Fcgr2b in the B6.Sle1(111-148) strain was confirmed at the protein level. The mAb K9.361, which is specific for the FcgRIIB Ly17.2 allotype, was used to measure the levels of FcgRIIB on B-cell subpopulations. Four-color flow cytometry analysis of splenocytes obtained on day 9 of the anti-SRBC response revealed background levels of K9.361 staining on B6.Sle1(111-148) B-cell subpopulations as compared to the strong staining of B6 control and B6.Sle1a(15-353) GC (blue line in histograms) and non-GC (red line in histograms) B cells (Figure 3a ). In addition, the levels of K9.361 staining on both B6 and B6.Sle1a(15-353) GC B cells were at least fivefold higher compared with their non-GC counterparts. We also performed histological analysis (Figure 3b ) of spleen sections obtained on day 9 of the anti-SRBC response by staining with anti-IgD (red) and K9.361 (green). While elevated levels of K9.361 staining were seen on IgD neg B cells in B6 and B6.Sle1a(15-353) GCs, this staining was undetectable in B6.Sle1(111-148) GCs, further supporting the conclusion that the Fcgr2b allele in B6.Sle1(111-148) mice is not of B6 but of NZW/NZM2410 origin. Interestingly, however, we found levels of 2.4G2 staining on B6.Sle1a(15-353) GC B cells at least eightfold higher than that on non-GC B cells (Figure 4a , lower middle panel), analogous to that observed on B6 splenic GCs.
To corroborate these findings, we next performed histological analysis as described above in Figure 1c . As shown in Figure 4b , two sets of parallel spleen sections from each genotype were stained. Although 2.4G2 staining in the FDC-rich regions in GCs of all three strains was comparable, elevated levels of 2.4G2 staining was observed in the FDC-poor regions of B6 and B6.Sle1 GCs as compared to substantially lower or undetectable levels of staining in these regions in B6.Sle1(111-148) GCs (shown in arrows, right most column), analogous to that observed in B6.Sle1 GCs (Figure 1c) (Figure 4c ). In total, these data indicated a defect in the upregulation of FcgRIIB 
The Fcgr2b
NZW allele is associated with an increased IgG production We screened a new cohort of 10-to 12-month-old B6.Sle1(111-148) mice and confirmed as previously reported that these mice do not produce anti-chromatin or anti-dsDNA antibodies (data not shown). To further determine the functional consequences of the expression of the Fcgr2b NZW allele, we compared antibody levels in SRBC-immunized mice. There was no significant difference between the three strains in levels of either SRBCspecific IgM or total IgM (Figures 5a and d) . In contrast, B6.Sle1(111-148) mice produced significantly higher levels of SRBC-specific IgG and total IgG (Figures 5b and e) . This resulted in a significantly skewed IgG/IgM ratio for both the response to the T-dependent antigen and the total circulating immunoglobulin (Figures 5c and f) .
We have recently demonstrated that Fcgr2b deficiency regulated the production of autoreactive primary antibody-forming cells (AFCs) by BCR transgenic B cells independent of GC events. 15 We, therefore, compared the effect of the Fcgr2b NZW and B6 alleles on AFC formation 6 and 14 days after SRBC immunization. At 6 days in the spleen and 14 days in the BM, FcgRIIB expression on AFCs mirrored that on GC B cells with a significantly reduced level associated with the NZW allele (Figure 6a ). Surface IgM expression on both CD138 þ B220 þ plasmablasts and CD138 þ B220 À/lo PC was significantly lower in B6.Sle1(111-148) than in either B6 or B6.Sle1a(15-353) mice (data not shown). Consistent with the surface expression, the percentage of intracellular IgM þ was also significantly lower in both (Figure 6b ), while the percentage of intracellular IgG þ PCs was significantly higher in B6.Sle1(111-148) spleens at 6 days p.i. (Figure 6c) . Finally, the percentage of total CD138 þ B220 À/lo PCs was significantly higher in B6.Sle1(111-148) spleens at 6 and 14 days p.i. and BM 6 days p.i. (data not shown). These results were confirmed by the presence of a larger number of IgG þ AFCs in the spleen (although it did not reach statistical significance) and the BM (Po0.03) at 6 days p.i. in B6.Sle1(111-148) mice (Figure 6d ). The same type of analysis was performed on mice following secondary immunization, and we did not observe any specific difference in B6.Sle1(111-148) mice (data not shown). Together, these data suggest that Fcgr2b NZW regulates the primary AFC pathway by increasing their number and by accelerating class switching.
Discussion
We have used NZM2410/NZW-derived congenic strains to analyze the phenotypes associated with the Fcgr2b NZW allele independently from the flanking lupus susceptibility loci Sle1a and Sle1b. We have used a combination of genomic, transcriptional and histological methods to show that the 2-3 Mb congenic interval of B6.Sle1(111-148) contains the NZW allele of Fcgr2b, while the strain B6.Sle1a (15- 16 and Fcrlb (FcRY or Freb1) 17 that are contained in the B6.Sle1(111-148) interval, and potentially not in the B6.Sle1a(15-353) interval since they are situated in the region of recombination between the D1MIT270 and D1MIT147 markers. These two FcR family members are differentially expressed on B cells, including GC B cells, but their function is yet unknown. 18, 19 Interestingly, FCRL3, a member of this family in humans, is associated with RA and other autoimmune conditions, including lupus. 20 We are currently investigating whether one or both of these genes present allelic differences between NZW and B6. If it were the case, it would be possible that these genes could indirectly regulate Fcrg2b on GC B cells. The most likely explanation, however, is that the failure to upregulate Fcgr2b expression on GC B cells is regulated in cis by the Fcgr2b NZW allele.
In spite of the low expression of FcgRIIB on GC B cells, the number and size of GCs were equivalent between B6.Sle1(111-148) and B6 mice. We have found, however, that B6.Sle1(111-148) mice produced significantly more anti-SRBC IgG and total IgG, which was correlated with a greater number of primary AFCs that downregulated surface and intracellular IgM in favor of IgG. We have confirmed recent results showing FcgRIIB expression on PC, 21 but contrary to the other autoimmune strains NZB and MRL in which FcgRIIB is virtually absent on the PC surface, the NZW allele is associated with only a modest reduction of expression on PCs. Future experiments will have to be performed to assess whether this modest reduction is sufficient to decrease PC turnover through decreased apoptosis in Fcgr2b NZW -carrying mice, as it has been shown for Fcgr2b-deficient mice. 21 Interestingly, the kinetics of FcgRIIB expression on PC as well as the absence of Fcgr2b NZW allele contribution to autoimmunity ZSM Rahman et al our previous findings 15 that this receptor regulates primary T-dependent immune responses.
Overall, our results indicate that Fcgr2b NZW functions as an Fcgr2b hypomorph in regulating AFC numbers and class switching independent of GC reactions. This concurs with previous findings that showed that an Fcgr2b deficiency allows the accumulation of autoreactive PC. 7, 10 Interestingly, however, the Fcgr2b NZW Fcgr2b NZW allele contribution to autoimmunity ZSM Rahman et al maintenance of B-cell tolerance. We are in the process of testing whether a similar GC 'bypass' also occurs in the NZM2410 strain, and what role, if any, Fcgr2b plays in this context. We have previously documented the highly interactive nature of the Sle1 loci, 23 and we have specifically shown that the interval including Sle1a, Sle1b and the intervening region resulted in autoimmune phenotypes that were much stronger than the simple additive effects of Sle1a plus Sle1b. We speculate that Fcgr2b NZW contributes to these epistatic effects. In addition, we have previously shown that both NZM2410 and NZW mice present an accumulation of PC in the spleen. 24 Although we were not able to map the entire phenotype to any single Sle locus, it is also temping to speculate that reduced FcgRIIB expression may contribute to this phenotype, as suggested by our data in Figure 6 . Interestingly, close examination of our results in Figures 5 and 6 suggests that Sle1a also impacts the immune response to SRBC immunization, including the number of class-switched PCs. Detailed studies of the interaction between Fcgr2b NZW and the other Sle loci in the context of plasma cell development will be necessary to fully understand how the restoration of normal FcgRIIB expression on NZM2410 B cells was sufficient to abrogate disease.
11

Materials and methods
Mice and immunization
The B6.NZM2410-Sle1 (B6.Sle1), B6.NZM2410-Sle1a(15-353) (B6.Sle1a (15-353) ) and B6.NZM2410-Sle1(111-148) (B6.Sle1(111-148)) mice have already been described. 12, 13 These mice along with B6 controls were bred at the University of Florida Animal Care Center. B6;129S4-Fcgr2b tm1Rav /J (B6.RIIB À/À ) were kindly supplied by Dr Jeffrey Ravetch (The Rockefeller University, New York, NY, USA). All mice were maintained in a pathogen-free barrier facility and all procedures were approved by the JU or UF IACUCs. Cohorts of at least three mice per strain were immunized intra-peritoneally with 200 ml of SRBC diluted 10% v/v in sterile 0.9% saline solution. Spleens, BM and terminal sera were collected after either 6, 9, or 14 days, as indicated in the text. All mice were used between 8 and 20 weeks of age, except for the autoantibody screens, and cohorts of both males and females were used without significant differences.
Congenic strain genotyping
All available MIT microsatellite markers located within 170 and 173 Mb on chromosome 1 were screened for polymorphism between B6 and NZW and then used to assess the haplotype distribution across the B6.Sle1a 
Immunohistology
Spleen cryostat sections (5-6 mm) were prepared as described. 25 Immunohistology was performed using the antibodies listed above and the stained sections were analyzed using a fluorescence microscopy (Leitz Diaplan, Wetzlar, Germany) and images were captured as described. 26 Flow cytometry Four-color flow cytometric analysis was performed on cell suspensions prepared from spleens of naive and immunized mice stained with multiple combinations of antibodies listed above. Biotinylated Abs were detected with SA-CyChrome. Stained cells were analyzed using a Coulter Epics XL/MCL or a Facscalibur (BD Biosciences) analyzer. Data were analyzed using the FlowJo software (Treestar, San Carlos, CA, USA).
GC B-cell sorting, RNA extraction and real-time RT-PCR B220 high IgD neg PNA þ GC B cells were sorted using a MoFlo fluorescent activated high-speed sorter (Dako Cytomation, Glostrup, Denmark). RNA purification, reverse transcription of RNA, real-time RT-PCR and generating raw RQ (relative quantification) values for FcgRIIB gene expression in GC B cells were performed as described. 10 Antibody measurements All antibodies were detected by enzyme-linked immunosorbent assay (ELISA) in Immunolon II plates (Dynex, Chantilly, VA, USA). For anti-SRBC antibodies, the plates were coated with SRBC diluted at 1:1000 in PBS for 1 h at room temperature, then fixed with 0.5% gluteraldehyde. After blocking (3% BSA, 0.1% gelatin, 3 mM EDTA), sera were incubated in duplicate at 1:200 dilution for 2 h, and bound IgG antibodies were detected with an alkaline phosphatase-conjugated goat anti-mouse IgG antibody (Chemicon International, Temecula, CA, USA) at a 1:1000 dilution. Total IgM and IgG were detected by sandwich ELISA with sera diluted 1:200 000 as previously described. 27 Anti-chromatin IgG antibodies were detected in 10-to 12-month-old mice with plates coated with total histone and dsDNA as previously described.
28
Fcgr2b NZW allele contribution to autoimmunity ZSM Rahman et al Enzyme-linked immunospot (ELISPOT) assay AFCs were enumerated by ELISPOT as previously described. 24 Serially diluted RBC-depleted spleen and BM cells were added to multiscreen filter plates (Millipore, MA, USA) coated with 5 mg/ml goat antimouse IgG for 6 h at 37 1C. Bound cells were detected with HRP-conjugated-anti-IgG (Southern Biotechnology), and developed by 3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich, St Louis, MO, USA). AFCs were then counted and measured using a Bioreader 4000 Pro-x (BioSys, Germany).
Statistical analysis
Statistical significance was evaluated with the GraphPad Prism 4 software package and the specific tests were reported in the text (either Bonferroni's multiple comparison or variance F tests).
